New appointees, along with recently appointed Directors Peter Harwin and Interim CEO Jonathan Violin , PhD, provide a strong foundation for the company WALTHAM, Mass. , Nov. 11, 2024 /PRNewswire/ -- Crescent Biopharma, Inc.
("Crescent"), a private biotechnology company dedicated to advancing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced it has appointed Susan Moran , MD, MSCA, former Chief Medical Officer of RayzeBio, Inc., and Alexandra Balcom , MBA, CPA, Chief Financial Officer of Nuvalent, Inc., to its Board of Directors.
They join Jonathan Violin, PhD, Crescent's Interim Chief Executive Officer and Venture Partner at Fairmount , and Peter Harwin , Fairmount Co-founder, on the Board. "We are honored to have Dr. Moran and Ms.
Balcom join the Board. Their appointments ensure we are well situated for rapid growth as we work to deliver potentially best-in-class therapies to patients with solid tumors," said Dr. Violin.
"Dr. Moran brings deep experience in developing novel oncology therapeutics and Ms. Balcom offers a wealth of expertise in finance and operations, both at top-tier oncology companies.
We are all extremely excited by the potential impact of Crescent's pipeline, led by CR-001, our tetravalent PD-1 x VEGF bispecific antibody. CR-001 was specifically designed to uniquely recapitulate the groundbreaking cooperative binding mechanism of action that recently demonstrated superiority to p.
